S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
Log in

NASDAQ:LMNX - Luminex Stock Price, Forecast & News

$27.05
-0.48 (-1.74 %)
(As of 04/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$25.51
Now: $27.05▼
$28.10
50-Day Range
$23.09
MA: $25.37▼
$28.85
52-Week Range
$17.34
Now: $27.05▼
$30.90
Volume888,478 shs
Average Volume430,923 shs
Market Capitalization$1.22 billion
P/E RatioN/A
Dividend Yield1.31%
Beta0.74
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Read More
Luminex logo

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
Previous Symbol
CUSIP55027E10
CIK1033905
Webhttp://www.luminexcorp.com/
Phone512-219-8020

Debt

Debt-to-Equity Ratio0.04
Current Ratio3.49
Quick Ratio2.16

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio386.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$334.64 million
Price / Sales3.65
Cash Flow$0.44 per share
Price / Cash Flow61.82
Book Value$10.32 per share
Price / Book2.62

Profitability

EPS (Most Recent Fiscal Year)($0.21)
Net Income$-3,840,000.00
Net Margins-1.18%
Return on Equity-2.03%
Return on Assets-1.74%

Miscellaneous

Employees1,247
Outstanding Shares45,168,000
Market Cap$1.22 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:LMNX Rates by TradingView

Luminex (NASDAQ:LMNX) Frequently Asked Questions

How has Luminex's stock been impacted by COVID-19 (Coronavirus)?

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LMNX stock has decreased by 0.2% and is now trading at $27.05. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Luminex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Luminex.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Luminex.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) released its quarterly earnings data on Monday, February, 10th. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.08. The medical instruments supplier had revenue of $90.50 million for the quarter, compared to the consensus estimate of $90.27 million. Luminex had a negative return on equity of 2.03% and a negative net margin of 1.18%. Luminex's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.04 earnings per share. View Luminex's earnings history.

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex declared a quarterly dividend on Tuesday, February 18th. Stockholders of record on Thursday, March 19th will be paid a dividend of $0.09 per share on Thursday, April 9th. This represents a $0.36 annualized dividend and a yield of 1.33%. The ex-dividend date is Wednesday, March 18th. View Luminex's dividend history.

What guidance has Luminex issued on next quarter's earnings?

Luminex issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, February, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82-84 million, compared to the consensus revenue estimate of $87.74 million.

What price target have analysts set for LMNX?

3 brokerages have issued 12 month target prices for Luminex's stock. Their forecasts range from $21.00 to $32.00. On average, they expect Luminex's share price to reach $26.50 in the next year. This suggests that the stock has a possible downside of 2.0%. View analysts' price targets for Luminex.

Has Luminex been receiving favorable news coverage?

News coverage about LMNX stock has been trending very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Luminex earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutLuminex.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Micron Technology (MU), AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Alphabet (GOOG), Starbucks (SBUX), AT&T (T), Exxon Mobil (XOM) and Gilead Sciences (GILD).

Who are Luminex's key executives?

Luminex's management team includes the following people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $27.05.

How big of a company is Luminex?

Luminex has a market capitalization of $1.22 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe. View additional information about Luminex.

What is Luminex's official website?

The official website for Luminex is http://www.luminexcorp.com/.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


MarketBeat Community Rating for Luminex (NASDAQ LMNX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  378 (Vote Underperform)
Total Votes:  630
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: Return on Equity (ROE)
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel